Number IV: Erythema multiforme

Oral Diseases

Volumn 11, Issue 5, 2005, Pages 261-267

  Farthing, P ^a   Bagan, J V ^b   Scully, C ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmune; Erythema multiforme; Immunosuppressants; Oral; Skin; Vesiculobullous

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMINOPENICILLIN; ANTACID AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BARBITURIC ACID DERIVATIVE; BUSULFAN; CARBAMAZEPINE; CEPHALOSPORIN; CHLORMEZANONE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; IMMUNOMODULATING AGENT; LEVAMISOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PREDNISOLONE; QUINOLONE DERIVATIVE; SULFONAMIDE; TETRACYCLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALACICLOVIR;

APOPTOSIS; BIOPSY; BLISTER; CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE CLASSIFICATION; DOSE RESPONSE; ELECTROLYTE BALANCE; ERYTHEMA MULTIFORME; GENETIC PREDISPOSITION; HERPES SIMPLEX; HISTOPATHOLOGY; HLA SYSTEM; HYDRATION; HYPERSENSITIVITY REACTION; IMMUNOPATHOLOGY; INTRAVENOUS ADMINISTRATION; KERATINOCYTE; LABORATORY TEST; LIMB; METABOLITE; MORBIDITY; MORTALITY; MOUTH LESION; MOUTH MUCOSA; NUTRITIONAL SUPPORT; PEMPHIGUS; PLASMAPHERESIS; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REVIEW; SKIN DEFECT; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TISSUE INJURY; TOXIC EPIDERMAL NECROLYSIS; ULCER; VIRUS INFECTION; ADULT; ARTICLE; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOLOGY; MALE; PATHOGENICITY; PATHOLOGY; VIROLOGY;

ADULT; DIAGNOSIS, DIFFERENTIAL; EPIDERMAL NECROLYSIS, TOXIC; ERYTHEMA MULTIFORME; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MOUTH MUCOSA; SIMPLEXVIRUS; STEVENS-JOHNSON SYNDROME;

EID: 25144492823     PISSN: 1354523X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2005.01141.x     Document Type: Review

References (45)

1. Abdollahi M, Radfar M (2003). A review of drug-induced oral reactions. J Contemp Dent Pract 4: 10-31.
2. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H (2003). Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162: 1515-1520.
3. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC (2002). Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138: 1019-1024.
4. Aslanzadeh J, Helm KF, Espy MJ, Muller SA, Smith TF (1992). Detection of HSV-specific DNA in biopsy tissue of patients with erythema multiforme by polymerase chain reaction. Br J Dermatol 126: 19-23.
5. Aurelian L, Ono F, Burnett J (2003). Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J 9: 1-27.
6. Ayangco L and Rogers RS III (2003). Oral manifestations of erythema multiforme. Dermatol Clin 21: 195-205.
7. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993). Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129: 92-96.
8. Billiau A, Heremans H, Vermeire K, Matthys P (1998). Immunomodulatory properties of interferon-gamma. An update. Ann N Y Acad Sci 856: 22-32.
9. Brice SL, Krzemien D, Weston WL, Huff JC (1989). Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme. J Invest Dermatol 93: 183-187.
10. Carrozzo M, Togliatto M, Gandolfo S (1999). Erythema multiforme. A heterogeneous pathologic phenotype. Minerva Stomatol 48: 217-226.
11. Conejo-Mir JS, del Canto S, Munoz MA et al (2003). Thalidomide as elective treatment in persistent erythema multiforme; report of two cases. J Drugs Dermatol 2: 40-44.
12. Darragh TM, Egbert BM, Berger TG, Yen TS (1991). Identification of herpes simplex virus DNA in lesions of erythema multiforme by the polymerase chain reaction. J Am Acad Dermatol 24: 23-26.
13. de Roux Serratrice C, Serratrice J et al (2001). Stevens-Johnson syndrome followed by Gougerot-Sjogren syndrome. Presse Med 30: 531-532.
14. Diz Dios P, Scully C (2002). Adverse effects of antiretroviral therapy: focus on orofacial effects. Expert Opin Drug Saf 1: 307-317.
15. Farthing PM, Maragou P, Coates M, Tatnall F, Leigh IM, Williams DM (1995). Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme. J Oral Pathol Med 24: 9-13.
16. Huff JC (1988). Acyclovir for recurrent erythema multiforme caused by herpes simplex. J Am Acad Dermatol 18: 197-199.
17. Huff JC, Weston WL (1989). Recurrent erythema multiforme. Medicine (Baltimore) 68: 133-140.
18. Huff JC, Weston WL, Tonnesen MG (1983). Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 8: 763-775.
19. Imafuku S, Kokuba H, Aurelian L, Burnett J (1997). Expression of herpes simplex virus DNA fragments located in epidermal keratinocytes and germinative cells is associated with the development of erythema multiforme lesions. J Invest Dermatol 109: 550-556.
20. Iwai K, Miyawaki T, Takizawa T et al (1994). Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84: 1201-1208.
21. Katz J, Livneh A, Shemer J, Danon YL, Peretz B (1999). Herpes simplex-associated erythema multiforme (HAEM): a clinical therapeutic dilemma. Pediatr Dent 21: 359-362.
22. Knowles SR, Uetrecht J, Shear NH (2000). Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 356: 1587-1591.
23. Kokuba H, Imafuku S, Burnett JW, Aurelian L (1999). Longitudinal study of a patient with herpes-simplex-virus-associated erythema multiforme: viral gene expression and T cell repertoire usage. Dermatology 198: 233-242.
24. Kokuba H, Imafuku S, Huang S, Aurelian L, Burnett JW (1998). Erythema multiforme lesions are associated with expression of a herpes simplex virus (HSV) gene and qualitative alterations in the HSV-specific T-cell response. Br J Dermatol 138: 952-964.
25. Leigh IM, Mowbray JF, Levene GM, Sutherland S (1985). Recurrent and continuous erythema multiforme-a clinical and immunological study. Clin Exp Dermatol 10: 58-67.
26. Lozada F, Silverman S Jr (1978). Erythema multiforme. Clinical characteristics and natural history in fifty patients. Oral Surg Oral Med Oral Pathol 46: 628-636.
27. Lyell A (1979). Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol 100: 69-86.
28. Lyell A (1993). Drug-induced toxic epidermal necrolysis. 1. An overview. Clin Dermatol 11: 491-492.
29. Malmstrom M, Ruokonen H, Konttinen YT et al (1990). Herpes simplex virus antigens and inflammatory cells in oral lesions in recurrent erythema multiforme. Immunoperoxidase and autoradiographic studies. Acta Derm Venereal 70: 405-410.
30. Miura S, Smith CC, Burnett JW, Aurelian L (1992). Detection of viral DNA within skin of healed recurrent herpes simplex infection and erythema multiforme lesions. J Invest Dermatol 98: 68-72.
31. Molin L (1987). Oral acyclovir prevents herpes simplex virus-associated erythema multiforme. Br J Dermatol 116: 109-111.
32. Nassif A, Bensussan A, Dorothee G et al (2002). Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 118: 728-733.
33. Nesbit SP, Gobetti JP (1986). Multiple recurrence of oral erythema multiforme after secondary herpes simplex: report of case and review of literature. J Am Dent Assoc 112: 348-352.
34. Ng PP, Sun YJ, Tan HH, Tan SH (2003). Detection of herpes simplex virus genomic DNA in various subsets of Erythema multiforme by polymerase chain reaction. Dermatology 207: 349-353.
35. Paul C, Wolkenstein P, Adle H et al (1996). Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 134: 710-714.
36. Porter SR, Scully C (2000). Adverse drug reactions in the mouth. Clin Dermatol 18: 525-532.
37. Rasmussen HB, Jepsen LV, Brandrup F (1989). Penicillamine-induced bullous pemphigoid with pemphigus-like antibodies. J Cutan Pathol 16: 154-157.
38. Roujeau JC (1997). Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease, which differs from erythema multiforme. J Dermatol 24: 726-729.
39. Sayama K, Yonehara S, Watanabe Y, Miki Y (1994). Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 103: 330-334.
40. Schofield JK, Tatnall FM, Leigh IM (1993). Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 128: 542-545.
41. Scully C, Bagan JV (2004). Adverse drug reactions in the orofacial region. Crit Rev Oral Biol Med 15: 221-239.
42. Stewart MG, Duncan III NO, Franklin DJ, Friedman EM, Sulek M (1994). Head and neck manifestations of erythema multiforme in children. Otolaryngol Head Neck Surg 111: 236-242.
43. Sun Y, Chan RK, Tan SH, and Ng PP (2003). Detection and genotyping of human herpes simplex viruses in cutaneous lesions of erythema multiform by nested PCR. J Med Virol 71: 423-428.
44. Tatnall FM, Schofield JK, Leigh IM (1995). A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 132: 267-270.
45. Viard I, Wehrli P, Bullani R et al (1998). Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490-493.